INFI Hits All-time Low, MESO Gets Blasted Over MPC-150-IM Data, EYEN On Watch

(RTTNews) - The following are some of the pharma/biotech stocks that posted the biggest percentage decline today.

1. Infinity Pharmaceuticals Inc. (INFI)

Lost 45.42% to close Monday's (Nov.12) trading at $1.31.

News: The Company reported clinical and translational data from expansion cohorts of its phase IB study of IPI-549 in combination with Opdivo, dubbed MARIO-1. The data reported included those of 82 patients treated with IPI-549 at 40 mg daily, and Opdivo at 240mg IV once every two weeks.

Although the data demonstrated preliminary evidence of IPI-549 in combination with Opdivo to be clinically active in indications not expected to respond to Opdivo alone, investors were not impressed.

Among the 44 patients evaluable for activity, 15 patients showed a best response of stable disease or better, including one partial response in an advanced melanoma patient who progressed on immediate prior Opdivo therapy, according to the Company. Another partial response was observed in a patient with advanced mesothelioma.

2. Mesoblast Limited (MESO)

Lost 27.70% to close Monday's trading at $5.48.

News: The Company's phase II trial of allogeneic cell therapy candidate MPC-150-IM in end-stage heart failure patients implanted with a left ventricular assist device (LVAD) failed to achieve the primary endpoint of temporary weaning from full LVAD support.

However, MPC-150-IM achieved significant reduction in major gastrointestinal (GI) bleeding episodes and related hospitalizations, a complication affecting up to 40% of LVAD recipients, according to the Company.

3. Autolus Therapeutics plc (AUTL)

Lost 26.06% to close Monday's trading at $35.50.

Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies.

News: No news

Recent event:

-- On June 22, 2018, the Company went public on the Nasdaq Global Select Market, offering its American Depositary Shares at a price of $17.00 per ADS.

Pipeline:

-- AUTO1, under a phase I trial in patients with pediatric relapsed or refractory acute B lymphocytic leukemia, or pediatric ALL, and a phase I clinical trial in adult patients with ALL. -- AUTO2, under a phase I/II clinical trial in relapsed or refractory multiple myeloma. -- AUTO3, under phase I/II clinical trial in pediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia (AMELIA), and under phase I/II clinical trial in patients with diffuse large B-cell lymphoma (ALEXANDER). -- AUTO4 under phase I/II clinical trial in patients with relapsed or refractory TRBC1 positive selected T-Non-Hodgkin Lymphoma. -- AUTO5 in preclinical development.

Near-term Catalysts:

-- Present data from the ALEXANDER Study on December 1, 2018. -- Present data from the AMELIA Study on December 2, 2018.

4. Concert Pharmaceuticals Inc. (CNCE)

Lost 21.61% to close Monday's trading at $12.59.

News: The Company announced mixed interim topline results from the first two cohorts of its Phase 2a trial of CTP-543 in patients with moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles, resulting in patchy or complete hair loss.

At 24 weeks, patients treated with an 8 mg twice-daily dose of CTP-543 met the primary efficacy endpoint vs. placebo, with significant difference in the overall severity of alopecia tool (SALT) score from baseline. But for the 4 mg cohort, the differences were not significantly different from placebo.

Near-term Catalyst:

-- Results from the complete Phase 2a trial of CTP-543 in patients with moderate-to-severe alopecia areata, including the 12 mg cohort, are expected in the third quarter of 2019.

5. Eyenovia Inc. (EYEN)

Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments.

Lost 17.46% to close Monday's trading at $3.12.

News: No news

Upcoming event:

The Company is slated to release financial results for the third quarter ended September 30, 2018 on Tuesday, November 13, 2018, before the market opens.

For the second quarter of 2018, net loss was approximately $3.3 million, or $0.33 per share, compared to a net loss of about $1.0 million or $0.43 per share for the second quarter of 2017.